GleamWall
中文EN

PVCT PROVECTUS BIOPHARMACEUTICALS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%

Returns

ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x

Cash quality & payout

Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$336,108$617,140
R&D expense$1.90M$2.05M
SG&A expense$3.73M$3.10M
Operating income-$5.29M-$4.53M
Interest expense$5,338$13,591
Pretax income-$5.51M-$4.77M
Net income-$5.43M-$4.73M
EBITDA-$5.29M-$4.53M
EPS (basic)-0.01-0.01
EPS (diluted)-0.01-0.01
Weighted avg. shares (diluted)420.28M419.81M
Banking
Net interest income-$210,359-$239,073
Balance sheet
Cash & equivalents$251,291$307,442
Current assets$567,874$976,772
PP&E, net$3,000$4,863
Total assets$697,502$1.01M
Current liabilities$6.90M$6.98M
Total liabilities$7.00M$6.98M
Shareholders' equity-$6.30M-$5.96M
Shares outstanding420.28M420.28M
Cash flow statement
Operating cash flow-$3.33M-$3.28M
Financing cash flow$3.09M$2.75M
Depreciation & amortization$1,863$7,157
Stock-based compensation$1.24M$1.28M

Free plan shows the latest 2 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.